Syndax Pharmaceuticals, Inc. Common Stock Earnings Dividend

Syndax Pharmaceuticals, Inc. Common Stock’s revenue jumped 223.64% since last year same period to $64.86Mn in the Q1 2026. On a quarterly growth basis, Syndax Pharmaceuticals, Inc. Common Stock has generated -5.28% fall in its revenue since last 3-months.

Syndax Pharmaceuticals, Inc. Common Stock’s net profit jumped 49.71% since last year same period to $-42.67Mn in the Q1 2026. On a quarterly growth basis, Syndax Pharmaceuticals, Inc. Common Stock has generated 37.26% jump in its net profits since last 3-months.

Syndax Pharmaceuticals, Inc. Common Stock’s net profit margin jumped 84.46% since last year same period to -65.79% in the Q1 2026. On a quarterly growth basis, Syndax Pharmaceuticals, Inc. Common Stock has generated 33.76% jump in its net profit margins since last 3-months.

Syndax Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.45 - a 23.73% jump from last quarter’s estimates.

Syndax Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.45.

Syndax Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) jumped 51.02% since last year same period to -0.48 in the Q1 2026. This indicates that the Syndax Pharmaceuticals, Inc. Common Stock has generated 51.02% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Syndax Pharmaceuticals, Inc. Common Stock’s return on assets (ROA) stands at -0.25.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Syndax Pharmaceuticals, Inc. Common Stock’s return on equity (ROE) stands at -1.9.